Q-omics provides the consensus-scored MT-TS2 profile across patient tissues and cancer cell-line models. MT-TS2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MT-TS2 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, MT-TS2 RNA expression shows 8,030 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRP, COAD, and PCPG as cancer lineages where MT-TS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-TS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-TS2 survival associations across molecular data types. MT-TS2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-TS2 RNA expression–survival associations across cancer types. High MT-TS2 expression shows unfavorable associations in THCA and DLBC, but favorable associations in KIRP, PAAD, ACC and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for MT-TS2 RNA expression.
This table summarizes MT-TS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MT-TS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-TS2 shows lower tumor expression in KIRC, STAD and LUSC and higher tumor expression in COAD, HNSC and LUAD. The COAD box plot shows higher MT-TS2 RNA expression in tumor versus normal tissue (log2 FC = +1.058, t-test p < 0.001).
This table shows molecular features associated with MT-TS2 in patient tissues and cancer cell lines. In patient samples, MT-TS2 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
